Article Details

Brown Rudnick Assists ArriVent in $615M Cancer Drug Development Collaboration

Retrieved on: 2024-06-20 14:25:34

Tags for this article:

Click the tags to see associated articles and topics

Brown Rudnick Assists ArriVent in $615M Cancer Drug Development Collaboration. View article details on hiswai:

Excerpt

Jiangsu Alphamab Biopharmaceuticals, based in China, is a biopharmaceutical company that develops biotherapeutics for cancer treatment. Partners ...

Article found on: brownrudnick.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up